Developer docs
API playgroundTry for free, no card

Search company profiles

Medicinrådet

Full company profile

uuid004vf44

Namestring
Medicinrådet
Legal namestring
Medicinrådet
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Medicinrådet (the Danish Medicines Council) is an independent governmental health technology assessment (HTA) body established on January 1, 2017 by the board of Danish Regions (Danske Regioner). Headquartered in Copenhagen at Dampfærgevej 21-23 with 92 employees, the organization evaluates new medicines for use in the Danish hospital sector through structured 14, 16, or 18-week assessment processes, issuing formal recommendations categorized as "anbefalet" (recommended), "delvist anbefalet" (partially recommended), or "ikke anbefalet" (not recommended). Its outputs are the primary evidence base used by Amgros, the regional pharmaceutical procurement organization, to negotiate medicine prices on behalf of Denmark's five regions, making Medicinrådet's assessments operationally binding for hospital procurement across the country.

The Council's product portfolio centers on a searchable recommendations database (Anbefalingsdatabase) containing 376+ medicine assessments to date, treatment guidelines (Behandlingsvejledninger) that prioritize medicines within specific disease areas, and primary-sector tools including the Basislisten (basic medicines list) and Seponeringslisten (discontinuation list). It also publishes general recommendations for drug classes (e.g., PD-(L)1 inhibitors for metastatic cancer) and participates in joint European HTA assessments. In 2026, the Council launched two pilot projects with the Danish Alliance for Real-World Evidence (DARE) to analyze post-market effectiveness of recommended cancer medicines, signaling expansion into real-world data analytics.

Medicinrådet operates as a non-commercial public entity funded entirely through the Danish healthcare system administrative budget by Danske Regioner, with no product sales, fees, or licensing revenue. It does not develop technology products; rather, its "technology" is its evidence evaluation methodology, prioritization principles (independence, effectiveness documentation, cost-effectiveness, etc.), and integration with the regional procurement system. Pharmaceutical companies engage the Council by submitting assessment applications, and recommendations directly shape which medicines are procured and reimbursed across Danish hospitals. The organization also maintains an active LinkedIn presence and email newsletter, using medicinraadet.dk as its primary dissemination channel for recommendations, guidelines, and news.

Short descriptiontext

Medicinrådet (Danish Medicines Council) is an independent governmental health technology assessment body, established in 2017 by Danish Regions, that evaluates and recommends new hospital medicines for Denmark's five regional healthcare authorities, guiding national procurement and price negotiations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCopenhagen, Denmark
HQ citystring
Copenhagen
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
health technology assessment, medicine recommendations, clinical guidelines, hospital drug evaluation, pharmaceutical assessment
Industry1 code
PRIMARYHLAJACAF
Health Technology Assessment (HTA) & Reimbursement Policy Bodies
Healthcare & Life Sciences/Public Health, Government & Regulators/Health Policy, Regulation & Compliance Authorities
NAICS code2 codes
  • Administration of Public Health Programs923120
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Health Technology Assessment
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Governmental funding
TypeLicensing Royalties
Description

Medicinrådet is a governmental body established by Danish Regions (Regionernes Lønnings- og Takstnævn) on January 1, 2017. It does not generate commercial revenue. The organization is funded through the Danish healthcare system administrative budget, not through product sales or fees.

medicinraadet.dk
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Medicinrådet is a governmental Health Technology Assessment (HTA) body that evaluates new medicines for the Danish hospital sector, producing evidence-based recommendations used to guide procurement across Danish hospitals and regions. The organization assesses applications from pharmaceutical companies through structured processes, issuing recommendations classified as recommended, partially recommended, or not recommended, which then serve as the basis for price negotiations conducted by Amgros.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 376+ medicine assessments completed with 232 recommended, 35 partially recommended, and 109 not recommended
+1 more record
Product overview1 text field

Medicinrådet (Danish Medicines Council) operates as a unified guidance platform providing independent recommendations on new medicines for the Danish hospital sector. The core offering consists of a recommendations database with 376 total assessments across three recommendation categories (232 recommended, 35 partially recommended, 109 not recommended), complemented by treatment guidelines (Behandlingsvejledninger) that prioritize medicines for specific diseases. For primary healthcare, the organization maintains the Basislisten (basic medicines list) and Seponeringslisten (discontinuation list). Additional products include general immunotherapy recommendations for metastatic cancer, participation in joint European HTA assessments, and real-world data partnerships for post-market surveillance.

Product and service9 records
1Recommendations Database (Anbefalingsdatabase)
CategoryCore recommendation service
Description

A searchable database of all medicine assessments, recommendations, and treatment guidelines issued by Medicinrådet, containing 232 recommended, 35 partially recommended, and 109 not recommended medicines. It is used by Danish Regions, hospitals, pharmaceutical companies, and healthcare professionals to access authoritative recommendations.

2Treatment Guidelines (Behandlingsvejledninger)
CategoryCore recommendation service
Description

Treatment guidelines that compare multiple medicines for specified diseases and produce a prioritized list of recommended medicines for patients. Used by Danish hospital clinicians and procurement teams to standardize treatment selection.

3Medicine Recommendations (Lægemiddelrekommandationer)
CategoryCore recommendation service
Description

Prioritized recommendations for medicines within specific disease areas, serving as a guide for hospital treatment decisions across Danish Regions.

4General Recommendation for Immunotherapy for Metastatic Cancer
CategoryTherapeutic-area recommendation
Description

General recommendation covering PD-(L)1 inhibitors and similar immunotherapy drug classes for metastatic cancer, applicable across multiple indications within Medicinrådet's scope.

5Basislisten (Basic List)
CategoryPrimary-sector guidance
Description

National basic list for general practitioners providing recommended medicines for primary healthcare settings. Used by primary care physicians across Denmark to guide first-line prescribing.

6Seponeringslisten (Discontinuation List)
CategoryPrimary-sector guidance
Description

List of medicines that should be discontinued or replaced in primary sector treatment guidelines. Used by general practitioners to update prescribing practices.

7Preparation Notifications (Præparatanmeldelser)
CategoryPrimary-sector guidance
Description

Notifications of new medicines for primary sector healthcare providers, enabling quick awareness of new drug approvals. Used by general practitioners to stay informed about newly available primary-sector medicines.

8Joint European Assessments (Fælles europæiske vurderinger)
CategoryInternational HTA collaboration
Description

Participation in joint European health technology assessments (HTA) with other Nordic and European bodies, producing collaborative assessments for cross-border use.

9Real-World Data Partnership (Partnerskab for real-world data)
CategoryData initiative
Description

Collaboration with the Danish Alliance for Real-World Evidence (DARE) to analyze real-world effectiveness data of recommended medicines, supporting post-market surveillance and assessment refinement.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Danish Alliance for Real-World Evidence (DARE)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

In 2026, Medicinrådet initiated two pilot projects with DARE (Danish Alliance for Real-World Evidence) to examine the effectiveness of Medicinrådets cancer drug recommendations. DARE will analyze data on the effects of recommended medicines.

medicinraadet.dk
Strategic tierFlagshipTypeOthers
Description

Medicinrådet was established on January 1, 2017 by the board of Danish Regions (Regionernes Lønnings- og Takstnævn). Danish Regions is the parent organization that established Medicinrådet based on experiences from previous initiatives such as RADS and KRIS.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Amgros is the pharmaceutical procurement organization that handles price negotiations with pharmaceutical companies on behalf of Danish Regions. Medicinrådets assessments provide the evidence base and recommendations that Amgros uses in its price negotiations, improving the negotiation foundation.

4DARE (Danish Alliance for Real-World Evidence)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on real-world data (RWD) to analyze the effectiveness of recommended medicines in clinical practice.

medicinraadet.dk
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

UK's national HTA body issuing clinical and cost-effectiveness recommendations for NHS-funded medicines. Directly comparable to Medicinrådet as the most influential national HTA agency, sharing the same single-payer HTA logic, recommendation taxonomy, and NHS-style pricing/negotiation integration.

TypeDirect peer
Description

Netherlands' HTA body managing the GVS/conditional reimbursement system for hospital drugs. Comparable in establishing reimbursement conditions tied to outcomes and in collaborating with the Ministry of Health on managed entry agreements.

3TLV (Tandvårds- och läkemedelsförmånsverket)
TypeDirect peer
Description

Sweden's Dental and Pharmaceutical Benefits Agency that decides which medicines are subsidized. Directly comparable as a Nordic counterpart with similar scope, population size, and side-by-side HTA + pricing function — likely the most culturally analogous peer.

4IQWiG (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen)
TypeDirect peer
Description

Germany's independent HTA body producing benefit assessments (early benefit assessment, Nutzenbewertung) that inform GKV-Spitzenverband price negotiations. Directly comparable in mandate and independence principle, though operates in a larger market and within AMNOG framework.

5AIFA (Agenzia Italiana del Farmaco)
TypeDirect peer
Description

Italy's national medicines agency combining regulatory, HTA, and pricing/pricing negotiation functions. Comparable as a state agency integrating scientific assessment with reimbursement decisions.

6HAS (Haute Autorité de Santé)
TypeDirect peer
Description

France's national HTA authority issuing SMR/ASMR opinions that drive price negotiations with CEPS. Directly comparable as a multi-pillar HTA body covering clinical benefit, economic assessment, and public health guidance within a single-payer system.

7NoMA (Statens legemiddelverk)
TypeDirect peer
Description

Norwegian Medicines Agency handling HTA/market access decisions for Norway. Nordic peer with the closest regional context to Denmark and parallel collaboration in joint Nordic HTA initiatives.

8INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)
TypeDirect peer
Description

Portugal's national medicines authority handling HTA and pricing within the NHS. Comparable smaller-market EU HTA body with similar scope and statutory independence.

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medicinrådet

Health Technology Assessmentmedicinraadet.dk

Medicinrådet (Danish Medicines Council) is an independent governmental health technology assessment body, established in 2017 by Danish Regions, that evaluates and recommends new hospital medicines for Denmark's five regional healthcare authorities, guiding national procurement and price negotiations.

What Medicinrådet does

Medicinrådet (the Danish Medicines Council) is an independent governmental health technology assessment (HTA) body established on January 1, 2017 by the board of Danish Regions (Danske Regioner). Headquartered in Copenhagen at Dampfærgevej 21-23 with 92 employees, the organization evaluates new medicines for use in the Danish hospital sector through structured 14, 16, or 18-week assessment processes, issuing formal recommendations categorized as "anbefalet" (recommended), "delvist anbefalet" (partially recommended), or "ikke anbefalet" (not recommended). Its outputs are the primary evidence base used by Amgros, the regional pharmaceutical procurement organization, to negotiate medicine prices on behalf of Denmark's five regions, making Medicinrådet's assessments operationally binding for hospital procurement across the country.

The Council's product portfolio centers on a searchable recommendations database (Anbefalingsdatabase) containing 376+ medicine assessments to date, treatment guidelines (Behandlingsvejledninger) that prioritize medicines within specific disease areas, and primary-sector tools including the Basislisten (basic medicines list) and Seponeringslisten (discontinuation list). It also publishes general recommendations for drug classes (e.g., PD-(L)1 inhibitors for metastatic cancer) and participates in joint European HTA assessments. In 2026, the Council launched two pilot projects with the Danish Alliance for Real-World Evidence (DARE) to analyze post-market effectiveness of recommended cancer medicines, signaling expansion into real-world data analytics.

Medicinrådet operates as a non-commercial public entity funded entirely through the Danish healthcare system administrative budget by Danske Regioner, with no product sales, fees, or licensing revenue. It does not develop technology products; rather, its "technology" is its evidence evaluation methodology, prioritization principles (independence, effectiveness documentation, cost-effectiveness, etc.), and integration with the regional procurement system. Pharmaceutical companies engage the Council by submitting assessment applications, and recommendations directly shape which medicines are procured and reimbursed across Danish hospitals. The organization also maintains an active LinkedIn presence and email newsletter, using medicinraadet.dk as its primary dissemination channel for recommendations, guidelines, and news.

Medicinrådet firmographics

Firmographics
Name
Medicinrådet
Legal name
Medicinrådet
Website
https://medicinraadet.dk
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
101–250 employees
Short description
Medicinrådet (Danish Medicines Council) is an independent governmental health technology assessment body, established in 2017 by Danish Regions, that evaluates and recommends new hospital medicines for Denmark's five regional healthcare authorities, guiding national procurement and price negotiations.
Ownership category
akta.pro rank

Medicinrådet industry classification

Industry
Product category
Health Technology Assessment
NAICS
Administration of Public Health Programs (923120), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAJACAF
Health Technology Assessment (HTA) & Reimbursement Policy Bodies
Healthcare & Life Sciences/Public Health, Government & Regulators/Health Policy, Regulation & Compliance Authorities

Keywords

  • Health technology assessment
  • Medicine recommendations
  • Clinical guidelines
  • Hospital drug evaluation
  • Pharmaceutical assessment

Where Medicinrådet is headquartered

Location

Headquarters

HQ city
Copenhagen
HQ country
Denmark
HQ region
Europe

Offices1 record

Markets served

Medicinrådet business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Others

Revenue model

  1. Governmental funding: Medicinrådet is a governmental body established by Danish Regions (Regionernes Lønnings- og Takstnævn) on January 1, 2017. It does not generate commercial revenue. The organization is funded through the Danish healthcare system administrative budget, not through product sales or fees.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Medicinrådet product offering

Product offering

Core offering

Medicinrådet is a governmental Health Technology Assessment (HTA) body that evaluates new medicines for the Danish hospital sector, producing evidence-based recommendations used to guide procurement across Danish hospitals and regions. The organization assesses applications from pharmaceutical companies through structured processes, issuing recommendations classified as recommended, partially recommended, or not recommended, which then serve as the basis for price negotiations conducted by Amgros.

Product overview

Medicinrådet (Danish Medicines Council) operates as a unified guidance platform providing independent recommendations on new medicines for the Danish hospital sector. The core offering consists of a recommendations database with 376 total assessments across three recommendation categories (232 recommended, 35 partially recommended, 109 not recommended), complemented by treatment guidelines (Behandlingsvejledninger) that prioritize medicines for specific diseases. For primary healthcare, the organization maintains the Basislisten (basic medicines list) and Seponeringslisten (discontinuation list). Additional products include general immunotherapy recommendations for metastatic cancer, participation in joint European HTA assessments, and real-world data partnerships for post-market surveillance.

Differentiator

Problem solved

Functional benefit

Products and services

  • Recommendations Database (Anbefalingsdatabase) A searchable database of all medicine assessments, recommendations, and treatment guidelines issued by Medicinrådet, containing 232 recommended, 35 partially recommended, and 109 not recommended medicines. It is used by Danish Regions, hospitals, pharmaceutical companies, and healthcare professionals to access authoritative recommendations.
  • Treatment Guidelines (Behandlingsvejledninger) Treatment guidelines that compare multiple medicines for specified diseases and produce a prioritized list of recommended medicines for patients. Used by Danish hospital clinicians and procurement teams to standardize treatment selection.
  • Medicine Recommendations (Lægemiddelrekommandationer) Prioritized recommendations for medicines within specific disease areas, serving as a guide for hospital treatment decisions across Danish Regions.
  • General Recommendation for Immunotherapy for Metastatic Cancer General recommendation covering PD-(L)1 inhibitors and similar immunotherapy drug classes for metastatic cancer, applicable across multiple indications within Medicinrådet's scope.
  • Basislisten (Basic List) National basic list for general practitioners providing recommended medicines for primary healthcare settings. Used by primary care physicians across Denmark to guide first-line prescribing.
  • Seponeringslisten (Discontinuation List) List of medicines that should be discontinued or replaced in primary sector treatment guidelines. Used by general practitioners to update prescribing practices.
  • Preparation Notifications (Præparatanmeldelser) Notifications of new medicines for primary sector healthcare providers, enabling quick awareness of new drug approvals. Used by general practitioners to stay informed about newly available primary-sector medicines.
  • Joint European Assessments (Fælles europæiske vurderinger) Participation in joint European health technology assessments (HTA) with other Nordic and European bodies, producing collaborative assessments for cross-border use.
  • Real-World Data Partnership (Partnerskab for real-world data) Collaboration with the Danish Alliance for Real-World Evidence (DARE) to analyze real-world effectiveness data of recommended medicines, supporting post-market surveillance and assessment refinement.

Quantifiable outcome

  • 376+ medicine assessments completed with 232 recommended, 35 partially recommended, and 109 not recommended
  • +1 more outcomes

Companies that use Medicinrådet

Customer profile

Segments1 record

Ideal customer profiles1 record

Medicinrådet technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Medicinrådet partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and flagship.

  • Danish Alliance for Real-World Evidence (DARE)coreStrategic or Co-development Partner · 1 January 2026In 2026, Medicinrådet initiated two pilot projects with DARE (Danish Alliance for Real-World Evidence) to examine the effectiveness of Medicinrådets cancer drug recommendations. DARE will analyze data on the effects of recommended medicines.
  • Danish RegionsflagshipOthersMedicinrådet was established on January 1, 2017 by the board of Danish Regions (Regionernes Lønnings- og Takstnævn). Danish Regions is the parent organization that established Medicinrådet based on experiences from previous initiatives such as RADS and KRIS.
  • AmgroscoreStrategic or Co-development PartnerAmgros is the pharmaceutical procurement organization that handles price negotiations with pharmaceutical companies on behalf of Danish Regions. Medicinrådets assessments provide the evidence base and recommendations that Amgros uses in its price negotiations, improving the negotiation foundation.
  • DARE (Danish Alliance for Real-World Evidence)coreStrategic or Co-development PartnerCollaboration on real-world data (RWD) to analyze the effectiveness of recommended medicines in clinical practice.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Medicinrådet competitors and assessment

Company assessment

Direct peers

  • NICE (National Institute for Health and Care Excellence): UK's national HTA body issuing clinical and cost-effectiveness recommendations for NHS-funded medicines. Directly comparable to Medicinrådet as the most influential national HTA agency, sharing the same single-payer HTA logic, recommendation taxonomy, and NHS-style pricing/negotiation integration.
  • Zorginstituut Nederland (ZIN): Netherlands' HTA body managing the GVS/conditional reimbursement system for hospital drugs. Comparable in establishing reimbursement conditions tied to outcomes and in collaborating with the Ministry of Health on managed entry agreements.
  • TLV (Tandvårds- och läkemedelsförmånsverket): Sweden's Dental and Pharmaceutical Benefits Agency that decides which medicines are subsidized. Directly comparable as a Nordic counterpart with similar scope, population size, and side-by-side HTA + pricing function — likely the most culturally analogous peer.
  • IQWiG (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen): Germany's independent HTA body producing benefit assessments (early benefit assessment, Nutzenbewertung) that inform GKV-Spitzenverband price negotiations. Directly comparable in mandate and independence principle, though operates in a larger market and within AMNOG framework.
  • AIFA (Agenzia Italiana del Farmaco): Italy's national medicines agency combining regulatory, HTA, and pricing/pricing negotiation functions. Comparable as a state agency integrating scientific assessment with reimbursement decisions.
  • HAS (Haute Autorité de Santé): France's national HTA authority issuing SMR/ASMR opinions that drive price negotiations with CEPS. Directly comparable as a multi-pillar HTA body covering clinical benefit, economic assessment, and public health guidance within a single-payer system.
  • NoMA (Statens legemiddelverk): Norwegian Medicines Agency handling HTA/market access decisions for Norway. Nordic peer with the closest regional context to Denmark and parallel collaboration in joint Nordic HTA initiatives.
  • INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde): Portugal's national medicines authority handling HTA and pricing within the NHS. Comparable smaller-market EU HTA body with similar scope and statutory independence.

Market position

Competitive moat4 records

Key risks1 record

Key highlights7 records

Customer concentration

Medicinrådet social profiles

Digital presence

Medicinrådet financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medicinrådet leadership team

Management profile

Number of profiles

Profiles2 records

Medicinrådet funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medicinrådet M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medicinrådet

What does Medicinrådet do?

Medicinrådet is a governmental Health Technology Assessment (HTA) body that evaluates new medicines for the Danish hospital sector, producing evidence-based recommendations used to guide procurement across Danish hospitals and regions. The organization assesses applications from pharmaceutical companies through structured processes, issuing recommendations classified as recommended, partially recommended, or not recommended, which then serve as the basis for price negotiations conducted by Amgros.

Is Medicinrådet a public or private company?

Medicinrådet is a private company. It is classified as state government owned and is currently operating.

When was Medicinrådet founded?

Medicinrådet was founded in 2017. It employs 101 to 250 people.

Where is Medicinrådet based?

Medicinrådet is headquartered in Copenhagen, Denmark, in the Europe region.

How does Medicinrådet make money?

One revenue line is on record: governmental funding.

Who are Medicinrådet's main competitors?

Direct peers on record are NICE (National Institute for Health and Care Excellence), Zorginstituut Nederland (ZIN), TLV (Tandvårds- och läkemedelsförmånsverket), IQWiG (Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen), AIFA (Agenzia Italiana del Farmaco), HAS (Haute Autorité de Santé), NoMA (Statens legemiddelverk) and INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde).

Does Medicinrådet have an API?

No public API is recorded for Medicinrådet.

What industry is Medicinrådet in?

Medicinrådet's product category is Health Technology Assessment. Its primary akta.pro industry code is HLAJACAF, Health Technology Assessment (HTA) & Reimbursement Policy Bodies. Its NAICS code is 923120 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals